Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013281 | 0.89 | BLM (0.50) | BLMPMP22HSD17B10MEN1KMT2A | |
| SCHEMBL20438453 | 0.83 | BLM (0.57) | BLMPMP22HSD17B10MEN1KMT2A | |
| SCHEMBL25793805 | 0.76 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL22110323 | 0.76 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL24982519 | 0.76 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL20463126 | 0.76 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL20445486 | 0.76 | TDP1 (0.39) | BLMPMP22KDM4ELMNATDP1 | |
| SCHEMBL22012734 | 0.75 | BLM (0.48) | BLMPMP22HSD17B10MEN1KMT2A | |
| SCHEMBL19884906 | 0.74 | MEN1 (0.41) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL20231178 | 0.73 | MEN1 (0.44) | MEN1KMT2AKDM4ELMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022087243-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |